Select Topic:
Browse by Series:

Interventional Radiology and More for HCC

Panelists: Ghassan K. Abou-Alfa, MD, Memorial Sloan Kettering Cancer Center; Anthony El-Khoueiry, MD, University of Southern California Norris Comprehensive Cancer Center; Catherine Frenette, MD, Scripps Green Hospital; A. Ruth He, MD, PhD, Georgetown University Medical Center; Riccardo Lencioni, MD, Sylvester Comprehensive Cancer Center
Published: Tuesday, Mar 06, 2018



Transcript: 

Riccardo Lencioni, MD: Interventional radiology is now able to offer a broad spectrum of interventions for patients with hepatocellular carcinoma, ranging from different tools for image-guided ablation with radiofrequency, microwaves, irreversible electroporation, and others. We can offer intraarterial therapy with chemoembolization or radioembolization, and we can combine different options to maximize the effect in individual patients. This is now supported by multiple studies, including randomized controlled trials and meta-analyses, and is part of the routine multidisciplinary management of patients with HCC in the referral centers.

I think 2018 is a special year because finally we understood lessons. We were able to work hard to truly bring more drugs, more agents, with a significant and meaningful effect to doctors treating hepatocellular carcinoma. I see this as the first step in this new chapter and definitely one of the next steps is to understand how to maximize the effect of these drugs by combining agents, for instance TKIs and immune checkpoint inhibitors, or different alternatives. And also, to understand the synergistic effect between interventional locoregional therapy and these novel systemically active agents.

Transcript Edited for Clarity 

SELECTED
LANGUAGE
Slider Left
Slider Right


Transcript: 

Riccardo Lencioni, MD: Interventional radiology is now able to offer a broad spectrum of interventions for patients with hepatocellular carcinoma, ranging from different tools for image-guided ablation with radiofrequency, microwaves, irreversible electroporation, and others. We can offer intraarterial therapy with chemoembolization or radioembolization, and we can combine different options to maximize the effect in individual patients. This is now supported by multiple studies, including randomized controlled trials and meta-analyses, and is part of the routine multidisciplinary management of patients with HCC in the referral centers.

I think 2018 is a special year because finally we understood lessons. We were able to work hard to truly bring more drugs, more agents, with a significant and meaningful effect to doctors treating hepatocellular carcinoma. I see this as the first step in this new chapter and definitely one of the next steps is to understand how to maximize the effect of these drugs by combining agents, for instance TKIs and immune checkpoint inhibitors, or different alternatives. And also, to understand the synergistic effect between interventional locoregional therapy and these novel systemically active agents.

Transcript Edited for Clarity 
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x